Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
86.43
-4.98 (-5.45%)
Sep 6, 2024, 4:00 PM EDT - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 120.18, with a low estimate of 76 and a high estimate of 168. The average target predicts an increase of 39.05% from the current stock price of 86.43.
Analyst Consensus: Buy
* Price targets were last updated on Aug 5, 2024.
Analyst Ratings
The average analyst rating for BPMC stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 6 |
| Buy | 4 | 5 | 6 | 5 | 5 | 6 |
| Hold | 3 | 2 | 4 | 4 | 4 | 4 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 15 | 15 | 17 | 15 | 15 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $130 → $133 | Strong Buy | Maintains | $130 → $133 | +53.88% | Aug 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $130 → $138 | Strong Buy | Maintains | $130 → $138 | +59.67% | Aug 2, 2024 |
| Baird | Baird | Buy Maintains $112 → $127 | Buy | Maintains | $112 → $127 | +46.94% | Aug 2, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +50.41% | Aug 1, 2024 |
| Barclays | Barclays | Hold Maintains $75 → $105 | Hold | Maintains | $75 → $105 | +21.49% | Jul 29, 2024 |
Financial Forecast
Revenue This Year
504.99M
from 249.38M
Increased by 102.50%
Revenue Next Year
693.38M
from 504.99M
Increased by 37.31%
EPS This Year
-1.31
from -8.37
EPS Next Year
-1.31
from -1.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 580.7M | 901.3M | 1.3B | ||
| Avg | 505.0M | 693.4M | 941.5M | ||
| Low | 465.6M | 560.7M | 744.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 132.8% | 78.5% | 86.3% | ||
| Avg | 102.5% | 37.3% | 35.8% | ||
| Low | 86.7% | 11.0% | 7.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.75 | 3.22 | 6.84 | ||
| Avg | -1.31 | -1.31 | 1.67 | ||
| Low | -1.64 | -2.84 | -2.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.